Objective:To investigate the correlation between the change of blood glucose and liver function after oral glucose tolerance test in cirrhotic patients.Methods:36 cirrhotic patients were classified into A,B and C groups according to Child-Pugh score.36 cirrhotic patients and 12 normal controls were given oral glucose tolerance test(OGTT)of 75g glucose after over night fasting.Venous blood samples OGTT 0,30,60,120 and 180 minutes were obtained.Results: The OGTT 60 and 120 minute's blood glucose values in total cirrhotic group were significantly higher than that in the controls(P

BACKGROUND:Increasing evidence has shown that lovastatin with less toxicity to normal cels has crucial effects on proliferation, apoptosis and differentiation of various cancer cels. However, its roles in glioma stem cels remain unclear.
OBJECTIVE:To explore the effect of lovastatin on proliferation and apoptosis of glioma stem cels.
METHODS: Flow cytometric sorting was used to separate glioma stem cels from human glioblastoma cel line U87. Effects of lovastatin on the proliferation and apoptosis of glioma stem cels were determined by MTT and flow cytometry, respectively. Furthermore, expression levels of Ki67, Bax and Bcl-2 in glioma stem cels treated with lovastatin were detected using western blot analysis.
RESULTS AND CONCLUSION: The CD133-positive glioma stem cels were sorted from human glioblastoma cel line U87 with a positive percentage of 85%. MTT assay showed that lovastatin inhibited the proliferation of glioma stem cels in dose (5, 10, 20 μmol/L)- and time (24, 48, 72, 96 hours)-dependent manners. Flow cytometry analysis showed that 10 μmol/L lovastatin (48 hours) induced apoptosis in glioma stem cels. In addition, the expression level of Ki67 was decreased by lovastatin treatment in a dose-dependent manner, and the Bcl-2 and Bax expression levels were reduced and increased by 10 μmol/L lovastatin treatment, respectively. In conclusion, lovastatin can inhibit cel proliferation and induce apoptosis of glioma stem cels, and lovastatin may be a potential drug for treatment of brain tumors.

Objective　To investigate the expression level of serum microrna-493 (mir-493) in patients with acute cerebral infarction (ACI) and its relationship with the prognosis after thrombolysis.Methods　Seventy patients with ACI in our hospital from October 2019 to March 2021 were selected as the study group,and 70 patients with healthy physical examination during the same period were selected as the control group.The serum miR-493 levels of the study group before treatment,3 d,7 d after treatment were detected.Results　The serum miR-493 levels in the study group were higher than that before treatment at 3 days after treatment,however,the serum miR-493 levels in the study group were lower in each time period (P<0.05).Serum miR-493 levels before treatment and neurological deficits in ACI patients Degree,serum VEGF,Ang-2,CRP,and IL-6 levels were negatively correlated (P<0.05).Serum miR-493 levels before treatment,3 d,and 7 d after treatment in the study group with good prognosis were higher than those with poor prognosis patients (P<0.05).The area under the curve (AUC) of serum miR-493 predicting poor prognosis of ACI patients with thrombolytic therapy before treatment,3 d and 7 d after treatment were 0.748,0.851,0.879,respectively,and 7 d after treatment serum miR-493 predicted the largest AUC,and the best prediction sensitivity and specificity were 73.68% and 88.24%,respectively.Conclusion　The expression levels of serum miR-493 in patients with acute cerebral infarction are significantly reduced,and related to the prognosis of patients after thrombolysis,and has certain value in assisting clinical prediction of the prognosis of patients.